A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats

Ashay Bhatwadekar, J. V. Glenn, J. L. Figarola, S. Scott, T. A. Gardiner, S. Rahbar, A. W. Stitt

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. Aim: To explore the role of LR-90 in the progression of experimental diabetic retinopathy. Methods: Streptozotocin- induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy. Results: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001). Conclusion: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.

Original languageEnglish (US)
Pages (from-to)545-547
Number of pages3
JournalBritish Journal of Ophthalmology
Volume92
Issue number4
DOIs
StatePublished - Apr 1 2008
Externally publishedYes

Fingerprint

Diabetic Retinopathy
Pericytes
Methyl Green
Advanced Glycosylation End Products
Hematoxylin
Streptozocin
Microvessels
Drinking Water
Trypsin
Sprague Dawley Rats
LR-90
Digestion
Microscopy
Anti-Inflammatory Agents
Staining and Labeling
Light

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. / Bhatwadekar, Ashay; Glenn, J. V.; Figarola, J. L.; Scott, S.; Gardiner, T. A.; Rahbar, S.; Stitt, A. W.

In: British Journal of Ophthalmology, Vol. 92, No. 4, 01.04.2008, p. 545-547.

Research output: Contribution to journalArticle

Bhatwadekar, Ashay ; Glenn, J. V. ; Figarola, J. L. ; Scott, S. ; Gardiner, T. A. ; Rahbar, S. ; Stitt, A. W. / A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats. In: British Journal of Ophthalmology. 2008 ; Vol. 92, No. 4. pp. 545-547.
@article{4b9cb4188cc746a491f6d7fd65be70ca,
title = "A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats",
abstract = "Background: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. Aim: To explore the role of LR-90 in the progression of experimental diabetic retinopathy. Methods: Streptozotocin- induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy. Results: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001). Conclusion: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.",
author = "Ashay Bhatwadekar and Glenn, {J. V.} and Figarola, {J. L.} and S. Scott and Gardiner, {T. A.} and S. Rahbar and Stitt, {A. W.}",
year = "2008",
month = "4",
day = "1",
doi = "10.1136/bjo.2007.127910",
language = "English (US)",
volume = "92",
pages = "545--547",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - A new advanced glycation inhibitor, LR-90, prevents experimental diabetic retinopathy in rats

AU - Bhatwadekar, Ashay

AU - Glenn, J. V.

AU - Figarola, J. L.

AU - Scott, S.

AU - Gardiner, T. A.

AU - Rahbar, S.

AU - Stitt, A. W.

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Background: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. Aim: To explore the role of LR-90 in the progression of experimental diabetic retinopathy. Methods: Streptozotocin- induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy. Results: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001). Conclusion: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.

AB - Background: Diabetic retinopathy is associated with accumulation of advanced glycation end products in the retinal microvasculature. LR-90 is an effective multistage inhibitor of advanced glycation with renoprotective and anti-inflammatory properties. Aim: To explore the role of LR-90 in the progression of experimental diabetic retinopathy. Methods: Streptozotocin- induced diabetic Sprague-Dawley rats were treated with LR-90 (50 mg/l in drinking water) for up to 32 weeks. At the end of the study, eyes were enucleated and subjected to trypsin digestion and staining with light green/haematoxylin. Acellular capillaries and pericytes were quantified in random fields using light microscopy. Results: In the LR-90-treated diabetic animals, acellular capillary numbers were reduced to 1.63 (0.20) from 2.58 (0.49) (p<0.05) in diabetic controls. LR-90 treatment also restored the pericyte deficit from 18.12 (0.98) in diabetic rats to 24.19 (0.76) (p<0.001). Conclusion: These findings show that LR-90 can effectively inhibit important lesions of diabetic retinopathy. This agent has potential for preventing retinopathy in patients with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=41849131467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849131467&partnerID=8YFLogxK

U2 - 10.1136/bjo.2007.127910

DO - 10.1136/bjo.2007.127910

M3 - Article

C2 - 18211931

AN - SCOPUS:41849131467

VL - 92

SP - 545

EP - 547

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 4

ER -